Acuta Capital Partners LLC Purchases Shares of 74,307 Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Acuta Capital Partners LLC bought a new stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 74,307 shares of the company's stock, valued at approximately $398,000. Acuta Capital Partners LLC owned 0.12% of Corvus Pharmaceuticals at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of CRVS. Geode Capital Management LLC grew its stake in Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company's stock valued at $2,974,000 after purchasing an additional 102,869 shares during the last quarter. Jane Street Group LLC purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter valued at about $265,000. State Street Corp increased its holdings in Corvus Pharmaceuticals by 48.2% in the 3rd quarter. State Street Corp now owns 178,246 shares of the company's stock worth $941,000 after buying an additional 57,943 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Corvus Pharmaceuticals by 441.5% during the third quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company's stock worth $262,000 after purchasing an additional 40,404 shares during the last quarter. Finally, PKS Advisory Services LLC acquired a new position in shares of Corvus Pharmaceuticals in the 4th quarter valued at about $56,000. Hedge funds and other institutional investors own 46.64% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CRVS. Oppenheimer reissued an "outperform" rating and set a $15.00 price target (up from $14.00) on shares of Corvus Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $11.00 price objective on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 26th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.67.

Corvus Pharmaceuticals Stock Down 1.9 %

NASDAQ:CRVS traded down $0.07 on Wednesday, hitting $3.29. The stock had a trading volume of 425,373 shares, compared to its average volume of 651,243. The stock has a market cap of $223.94 million, a price-to-earnings ratio of -3.53 and a beta of 0.67. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.43 and a 1-year high of $10.00. The company has a fifty day moving average price of $3.64 and a two-hundred day moving average price of $5.56.

Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last announced its quarterly earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.06). As a group, analysts anticipate that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.